Entrada Therapeutics (TRDA) Equity Ratio (2020 - 2026)

Entrada Therapeutics' Equity Ratio history runs 7 years deep, the most recent figure standing at 0.81 for Q1 2026.

• In Q1 2026, Equity Ratio fell 5.88% year-over-year to 0.81; the TTM figure through Mar 2026 stood at 0.81 (down 5.88% YoY), while the FY2025 annual figure was 0.81, changed 0.4% from the prior year.
• Equity Ratio was 0.81 for Q1 2026 at Entrada Therapeutics, roughly flat from 0.81 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2022 to a low of 0.42 in Q2 2023.
• Historically, Equity Ratio has averaged 0.73 across 5 years, with a median of 0.81 in 2025.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio surged 254.98% in 2022, then tumbled 51.59% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.84 in 2022, then sank by 38.75% to 0.52 in 2023, then soared by 57.68% to 0.81 in 2024, then dropped by 0.4% to 0.81 in 2025, then slipped by 0.49% to 0.81 in 2026.
• The last three Equity Ratio figures came in at 0.81 (Q1 2026), 0.81 (Q4 2025), and 0.83 (Q3 2025), per Business Quant data.